ClinicalTrials.gg
CompletedNCT00330460Updated Jan 24, 2011Results posted

A Randomized, Double-Blind Study to Compare the Efficacy of Treatment With Denosumab Versus Alendronate Sodium in Postmenopausal Women With Low Bone Mineral Density.

A Phase 3 interventional study of Alendronate and Denosumab in Osteoporosis and Osteopenia, sponsored by Amgen. Completed. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-01-24.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,189
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.

Enrollment
4th of 64
1,189 · median 90
Started
2006
with 4 others
Phase 3
24 of 64
2 open now
Registered
6th of 64
by date
Lead sponsor
22 of 64
Amgen

Among the 64 studies testing denosumab in Osteoporosis, this one is the 4th largest by enrollment, is one of 5 that started in 2006, is one of 24 in phase 3, and was the 6th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies testing denosumab in Osteoporosis, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether in postmenopausal women with low bone mineral density, the mean percent change in total hip BMD in subjects receiving denosumab is not less than that observed in subjects receiving alendronate sodium by more than a pre-specified non-inferiority margin.

03

Conditions studied

  • Osteoporosis
  • Osteopenia

Keywords

  • Osteoporosis
  • Osteopenia
  • AMG 162
  • Fracture - hip
  • Postmenopausal
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Patient is an ambulatory woman - Patient has BMD value that corresponds to a T-score of less than or equal to -2.0 (g/cm2) at the lumbar spine OR total hip within range specific to the study protocol. Exclusion Criteria: o Any disorder that compromises the ability of the subject to give written and/or to comply with study procedures

  • Evidence of any of the following per subject report, chart review or central laboratory result:

    1. Hyper- or hypothyroidism; however, subjects on stable thyroid hormone replacement therapy may be allowed per the following criteria:

      • If TSH level is normal, subject is eligible for the study.
      • If TSH level is below normal range, subject is not eligible for the study.
      • If TSH level is elevated (> 5.5 mIU/mL to 10.0 mIU/mL), serum T4 should be measured. If serum T4 is within normal range, subject is eligible. If serum T4 is outside of normal range, subject is not eligible for the study.
      • If TSH level is above 10.0 mIU/mL, subject is not eligible.
    2. Current hyper- or hypoparathyroidism
    3. Elevated transaminases

      • Serum (AST; serum glutamate-oxaloacetic transaminase [SGOT]) ³ 2.0 x (ULN)
      • Serum alanine aminotransferase (ALT; serum glutamate-pyruvate transaminase [SGPT]) ³ 2.0 x ULN
    4. Significantly impaired renal function as determined by serum creatinine ³ 2.0 mg/dL
    5. Current hypo- or hypercalcemia based on the central laboratory reference ranges
    6. Active gastric or duodenal ulcer; history of significant gastrointestinal bleed requiring hospitalization or transfusion, or dyspepsia or gastroesophageal reflux disease that is uncontrolled by medication
    7. Rheumatoid Arthritis, Paget's disease, Cushing's disease, hyperprolactinemia, or cirrhosis of the liver
    8. Known to have tested positive for , virus, or surface antigen
    9. (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years
    10. Any metabolic bone disease, eg, osteomalacia or osteogenesis imperfecta, which may interfere with the interpretation of the findings
    11. Malabsorption syndrome or any gastrointestinal disorders that are associated with malabsorption
  • Received any solid organ or bone marrow transplant
  • Vitamin D deficiency (25(OH) vitamin D level \< 12 ng/mL). Vitamin D repletion will be permitted and subjects may be re-screened; see Section 7.
  • Any laboratory abnormality which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
  • or poorly tolerant of ALN therapy; contraindications for ALN therapy include:

    1. Abnormalities of the esophagus, which delay esophageal emptying such as stricture or achalasia.
    2. Inability to stand or sit upright for at least 30 minutes.
    3. to ALN or other constituents of ALN tablets o Known sensitivity to mammalian cell derived drug products
  • Known intolerance to calcium supplements
  • Administration of intravenous bisphosphonate, or fluoride (except for dental treatment) or strontium ranelate
  • Oral bisphosphonate treatment:

    • ³ 3 months cumulatively in the past 2 years, OR
    • ³ 1 month in the past year, OR
    • Any use during the 3-month period prior to randomization
  • PTH or PTH derivatives (eg, teriparatide) within the last year
  • Administration of any of the following treatments within 3 months of randomization:

    1. Any SERM (eg, raloxifene)
    2. Tibolone
    3. Anabolic steroids or testosterone
    4. Glucocorticosteroids (³ 5 mg prednisone equivalent per day for more than 10 days)
    5. Systemic (oral, transdermal, topical) hormone replacement therapy (local vaginal estrogen preparation will be allowed)
    6. Calcitonin
    7. Calcitriol or vitamin D derivatives
    8. Other bone active drugs including anti-convulsives (except benzodiazepines) and heparin
    9. Chronic systemic ketoconazole, androgens, ACTH, cinacalcet, aluminum, lithium, protease inhibitors, methotrexate, gonadotropin-releasing hormone agonists
    10. Height, weight or girth which may preclude accurate DXA measurements
  • Less than 2 lumbar vertebrae (L1-L4) evaluable for DXA measurements
  • Both hips not evaluable by DXA (eg, history of bilateral hip replacement or pins in both hips)
  • Currently enrolled in or has not yet completed at least 1 month since ending other device or drug trial(s), or subject is receiving other investigational agent(s)
  • Any physical or psychiatric disorder which, in the opinion of the investigator, will prevent the subject from completing the study or interfere with the interpretation of the study results
  • Evidence of alcohol or substance-abuse within the last 12 months which the investigator believes would interfere with understanding or completing the study
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,189 participants (actual)

Study arms

  • Active comparator
    Alendronate

    Subjects in this arm will receive active ALN and placebo denosumab

    Drug: Alendronate

  • Experimental
    Denosumab

    Subjects in this arm will receive active denosumab and placbo ALN

    Drug: Denosumab

Interventions

06

What researchers measure

Primary outcomes

  1. Total Hip Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

Secondary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

  2. Trochanter Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

  3. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

  4. Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12

    Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 12 months

07

Results

Posted Jul 19, 2010

Participant flow

First Subject Enrolled: 26-Apr-2006 Last Subject Enrolled: 17-Nov-2006

Participant flow — Overall Study
MilestoneAlendronate 70 mg QWDenosumab 60 mg Q6M
Started595594
Completed553561
Not completed4233
Withdrew: Physician decision10
Withdrew: Adverse event108
Withdrew: Withdrawal by subject1817
Withdrew: Death11
Withdrew: Ineligibility determined13
Withdrew: Lost to follow-up83
Withdrew: Noncompliance21
Withdrew: Other10

Outcome measures

PrimaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6M
Total Hip Bone Mineral Density Percent Change From Baseline at Month 122.6 (2.4 to 2.8)3.5 (3.3 to 3.7)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (final values): 1 · 95% CI 0.7 to 1.2
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 124.2 (3.9 to 4.5)5.3 (5.0 to 5.6)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints) · Mean difference (final values): 1.1 · 95% CI 0.7 to 1.4
SecondaryTrochanter Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Trochanter Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6M
Trochanter Bone Mineral Density Percent Change From Baseline at Month 123.4 (3.1 to 3.7)4.5 (4.1 to 4.8)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints) · Mean difference (final values): 1 · 95% CI 0.6 to 1.4
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6M
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 121.8 (1.5 to 2.1)2.4 (2.2 to 2.7)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints) · Mean difference (final values): 0.6 · 95% CI 0.3 to 1
SecondaryDistal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12

Bone Mineral Density Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
12 months
Reported as:
Least squares mean · Percent Change from Baseline
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 12
Percent Change from BaselineAlendronate 70 mg QWDenosumab 60 mg Q6M
Distal 1/3 Radius Bone Mineral Density Percent Change From Baseline at Month 120.6 (0.3 to 0.8)1.1 (0.9 to 1.4)
Statistical analysis
  • Alendronate 70 mg QW vs Denosumab 60 mg Q6M · ANCOVA · p = 0.0001 (The reported p-value was the one-sided adjusted p-valued based on multiplicity adjustment of the secondary efficacy endpoints) · Mean difference (final values): 0.6 · 95% CI 0.3 to 0.9

Adverse events

Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alendronate 70 mg QW—37/586 (6.3%)261/586 (44.5%)
Denosumab 60 mg Q6M—34/593 (5.7%)270/593 (45.5%)
Most frequent serious events
Showing 10 of 79
Most frequent serious events
EventAlendronate 70 mg QWDenosumab 60 mg Q6M
PneumoniaInfections and infestations3/5861/593
DiverticulitisInfections and infestations0/5863/593
Non-cardiac chest painGeneral disorders2/5861/593
Tibia fractureInjury, poisoning and procedural complications2/5861/593
Transient ischaemic attackNervous system disorders2/5860/593
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/5862/593
Acute coronary syndromeCardiac disorders1/5860/593
BradycardiaCardiac disorders1/5860/593
Congestive cardiomyopathyCardiac disorders1/5860/593
Coronary artery diseaseCardiac disorders1/5861/593
Most frequent other events
Most frequent other events
EventAlendronate 70 mg QWDenosumab 60 mg Q6M
ArthralgiaMusculoskeletal and connective tissue disorders56/58675/593
Back painMusculoskeletal and connective tissue disorders56/58642/593
NasopharyngitisInfections and infestations43/58645/593
InfluenzaInfections and infestations42/58641/593
Pain in extremityMusculoskeletal and connective tissue disorders37/58631/593
ConstipationGastrointestinal disorders31/58636/593
Upper respiratory tract infectionInfections and infestations25/58636/593
DyspepsiaGastrointestinal disorders29/58634/593
HeadacheNervous system disorders32/58630/593
DiarrhoeaGastrointestinal disorders20/58630/593

Baseline characteristics

Age Continuous
Age Continuous(Years)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
Mean64.6 ± 8.364.1 ± 8.664.4 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
Female5955941189
Male000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Alendronate 70 mg QWDenosumab 60 mg Q6MTotal
White or Caucasian5025021004
Black or African American9716
Hispanic or Latino6966135
Asian8614
Japanese437
American Indian or Alaska Native022
Native Hawaiian or Other Pacific Islander011
Other3710
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009 Jan;24(1):153-61. doi: 10.1359/jbmr.0809010. PubMed 18767928 ↗
  • Gold DT, Horne R, Coon CD, Price MA, Borenstein J, Varon SF, Satram-Hoang S, Macarios D. Development, reliability, and validity of a new Preference and Satisfaction Questionnaire. Value Health. 2011 Dec;14(8):1109-16. doi: 10.1016/j.jval.2011.06.010. Epub 2011 Oct 1. PubMed 22152181 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2006, a primary completion of Nov 2007 and a completion of Jan 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 2 years 8 months after primary completion. A results delay was requested in Nov 2009.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2006
First posted
May 26, 2006
Start
May 2006
Primary completionActual
Nov 2007
CompletionActual
Jan 2008
Results delay requested
Nov 23, 2009
Results first posted
Jul 19, 2010
Last update
Jan 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00330460
Lead sponsor
Amgen
First posted
May 26, 2006
Start date
May 2006
Primary completion
Nov 2007
Completion
Jan 2008
Results posted
Jul 19, 2010
Last update
Jan 24, 2011

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion